Status: Recruiting
A Study of AMC6156 in People With Sarcopenia
This clinical trial aims to find out whether AMC6156 can improve physical function and is safe in older adults with sarcopenia. Participants will take AMC6156 or a placebo daily for 12 weeks, and their movement, strength, and safety will be regularly monitored through tests and checkups.
Participants needed: 80
Trial details
Phase: Phase 2Age: 65+Biological sex: AllType: InterventionalSponsor: Animuscure Inc.Updated: Jul 29, 2025Locations: 4
Eligibility criteria
Voluntary participation with written informed consent [+6]
Allergy to investigational drug [+9]